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ABSTRACT
Metastatic melanoma was the first malignancy in which immune checkpoint 
inhibitors demonstrated their successful efficacy. Currently, the knowledge on the 
interaction between the immune system and malignant disease is steadily increasing 
and new drugs and therapeutic strategies are overlooking in the clinical scenario. To 
provide a comprehensive overview of immune modulating drugs currently available 
in the treatment of melanoma as well as to discuss of possible future strategies in 
the metastatic melanoma setting, the present review aims at analyzing controversial 
aspects about the optimal immunomodulating treatment sequences, the search for 
biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations 
of drugs currently under investigation.
INTRODUCTION
In the last ten years, it has been amply demonstrated 
how the immune system represents a safe therapeutic 
target for solid tumors of different origin, first of all 
melanoma, characterized by a strong immunogenicity. 
Through the control and enhancement of the main immune 
checkpoints, therefore, we could stimulate the immune 
system to its fullest potential, ensuring control of the 
disease, and in a significant percentage of cases, response 
to treatment. 
Monoclonal antibodies (mAbs) able to block the 
immune checkpoints cytotoxic T-lymphocyte antigen-4 
(CTLA-4), programmed cell death protein 1 (PD-1) and 
its ligand (PD-L) have demonstrated high activity in 
metastatic melanoma and other solid tumors. 
CTLA-4 is an inhibitory molecule present on T cells: 
during the interaction between antigen presenting cells 
and lymphocytes, CTLA4 competes with co-stimulatory 
signals and interrupts T cell priming. By blocking CTLA-
4, the inhibitory effect on the priming phase is released 
leading to unrestricted T cell activation [1].
The PD-1 axis is another innate mechanism 
to reduce auto immunity and promote tolerance. 
Activated T cells express PD-1 receptor that, upon 
binding its ligands PD-L1 and PD-L2 (expressed 
in lymphoid cells, endothelial and epithelial cells, 
fibroblasts, dendritic cells, macrophages) induce T 
cell anergy. Melanoma cells express PD-L1 reducing 
the activity of infiltrating lymphocytes. By blocking 
the PD-1/PD-L1 interaction antitumor immunity can 
be restored [2–3] (Figure 1).
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Prognosis of patients with metastatic 
melanoma dramatically improved due to the use of 
immunocheckpoints inhibitors. Still, some aspects need to 
be elucidated in the clinical application of these drugs, and 
a large field of research is involved in understanding how 
to raise the bar of efficacy of immunotherapy.
Starting with the current knowledge on 
immunomodulatory drugs currently available, this review 
aims to analyze controversial aspects such as optimal 
treatment sequences, research of biomarkers of efficacy, 
and innovative features, such as combinations of drugs 
currently under investigation.
Biology of immune system 
The immune system defends the organism from 
pathogens, and has a major role in fighting cancer 
development. It is divided in innate and adaptive 
immunity. Innate immunity is composed by white blood 
cells [granulocytes, macrophages, dendritic and natural 
killer (NK) cells] with phagocytic, cytotoxic and secretory 
activity; soluble factors including acute phase proteins 
and complement. Innate immunity acts in the first phases 
of the immune response, recognizing tissue damage and 
triggering the adaptive immunity. It also plays a role in 
the elimination of damaged cells. Adaptive immunity is 
mainly composed of Lymphosites. Antigen presenting 
cells (APC), such as dendritic cells, recognize stranger 
antigens from damaged tissue acquire the ability to 
migrate in lymphonodes where they present the antigens 
to T lymphocytes. The T cell receptor (TCR) recognizes 
protein-derived antigen that are assembled in the major 
histocompatibility complex (MHC-I or MHC-II) on the 
surface of the antigen-presenting cells (APC). Multiple 
costimulatory signals are needed to switch on the full 
activation of T lymphocytes: for example, CD28, a co-
stimulatory receptor on the surface of T lymphocytes, 
binds to the B7 ligands, CD80 and CD86, on the surface 
of APC [110].
Activeted lymphocytes replicate and migrate to the 
dameged tissue. The CD4+ helper T cells and the CD8+ 
cytotoxic T cells (CTLs) are the main effectors against 
cancer cells: they manage humoral and cell-mediated 
response to kill cancer cells [8]. 
Some regulatory mechanisms are planned in order 
to control the intensity and duration of the T cell response 
or to mantein self tolerance: co-inhibitory immune 
checkpoint molecules, such as cytotoxic T-lymphocyte-
associated protein 4 (CTLA4), can be overexpressed 
from lymphocytes to antagonize those costimulatory 
signals that activate lymphocytes; programmed death 1 
(PD1) is another receptor expressed by lymphocytes that 
can lead them to exaustion when it recognizes its ligand; 
programmed death ligand (PDL)1 and PDL2 can be 
overexpressed by cancer cells. Other checkpoints include 
T cell Ig and mucin-domain-3-containing molecule 3 
(TIM3), lymphocyte-activation gene 3 (LAG3) and killer 
cell immunoglobulinlike receptor (KIR) [10, 11]. Cancer 
cells use these molecules to evade the immune system. 
All in all, modern immunocheckpoints inhibitors aim to 
stop these inhibitory signals to restore lymphocyts activity 
against cancer [111].
Immunocheckpoints agent: current status
Ipilimumab is the first and only anti-CTLA-4 drug 
approved by the FDA; it has demonstrated a survival at 3 
years of 20% with similar results obtained regardless its 
use as first or second line treatment. 
The first phase III trial was conducted in metastatic 
melanoma as second line treatment, and it compared 
ipilimumab 3 mg/kg every 3 weeks with GP-100 vaccine 
or the combination of both [4]. The study showed a 
significant improvement of survival (3.5 mo) for any of 
the ipilimumab-based arms. After a follow up of 2 years, 
overall survival was 13.7% for GP-100 monotherapy, 
21.6% for the combined ipilimumab and GP-100 arms, 
whilst 23.5% for ipilimumab monotherapy, was also 
confirmed after a longer follow up period [5]. Soon 
after these promising results, ipilimumab was studied 
as first line treatment as an addition to standard DTIC 
chemotherapy at a dose of 10 mg/kg for 4 doses followed 
by maintenance every 12 weeks. Ipilimumab showed its 
superiority against DTIC: median overall survival was 
11.2 months and 5 years survival rate was 18.2%, showing 
that efficacy was manteined in a subgroup of patients and 
observed also with longer follow up [6]. Tremelimumab 
is another anti-CTLA-4 monoclonal Antibody tested 
in metastatic melanoma patients. It is an IgG2 human 
mAb. In a phase III trial it was compared as a single 
agent to dacarbazine or temozolomide but it didn’t shows 
significant superiority in term of Overal Survival OS (11.8 
vs 10.7 months respectively for the tremelimumab and for 
chemotherapy). It is still unclear why the results were so 
different, also because a longer follow-up at 2 and 3 years 
showed results very similar to those of ipilimumab (26.4% 
and 20.7%, respectively) [7].
The second class of inhibitors of immune 
checkpoints are the anti PD (Programmed Death)-1 agents. 
The PD-1 receptor, normally expressed by activated T 
cells, B cells, monocytes, and natural killer (NK) cells, 
is an inhibitory receptor activated by its ligands PD-L1 
and PD-L2. PDL-1 is expressed in several cells, such 
as tumor cells and some host cells (myeloid, lymphoid, 
epithelial cells, antigen-presenting cells -APCs), so 
PD-1 works mainly in the tumor microenvironment [8, 
9]. The interaction between PD-1 and PD-L1 inhibits 
the CD8+ cytotoxic T lymphocyte proliferation and 
survival, and induces TILs apoptosis and promotes 
differentiation of CD4+ T cells into Treg cells. Nivolumab 
and Pembrolizumab, the main anti PD-1 inhibitors 
studied, have been recently approved for the treatment 
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of metastatic melanoma, with really promising results in 
terms of response rates and overall survival in different 
phase III trials. 
Nivolumab is a fully human immunoglobulin G4 
(IgG4) mAb anti-PD-1 agent. Several studies have been 
conducted both on BRAF v600 mutated and wild type 
patients. CheckMate 037 trial, 405 pretreated patients 
were enrolled, regardless of BRAF status, and randomized 
2:1 to receive nivolumab (272 patients) or chemotherapy 
(133 patients) [10]: objective response rate (the primary 
endpoint) was 31.7% in the nivolumab group vs. 10.6% 
in the chemotherapy group. No statistically significant 
differences were observed in terms of median PFS in 
nivolumab vs chemotherapy arms (respectively 4.7 vs. 4.2 
months). Grade 3-4 Adverse events incidence was lower 
in Nivolumab vs chemotherapy arm (respectively, 9% 
vs. 31%). Most frequent adverse events in the nivolumab 
group were pruritus, asthenia and diarrhea. 
In the double-blind phase III trial CheckMate 066 
418 untreated advanced BRAF wild-type melanoma 
patients were randomized to receive nivolumab or 
dacarbazine in first line. One year Survival rate was higher 
in nivolumab arm (72.9% vs. 42.1% - HR = 0.42; 99.79% 
CI, 0.25-0.73; P < 0.001) as median PFS was (5.1 vs. 2.2 
months in the nivolumab armand in the dacarbazine arm 
respectively - HR = 0.43; 95% CI, 0.34–0.56; P < 0.001). 
The objective response rate was 40.0% in nivolumab 
group and 13.9% in the dacarbazine group (HR = 4.06; 
P < 0.001). Grade 3-4 adverse event incidence was only 
11.7% [11].
Pembrolizumab is a humanized immunoglobulin 
G4 (IgG4) mAb anti-PD-1 agent. In the keynote-002 
randomised phase II trial, 540 ipilimumab pretreate 
metastatic melanoma patients were enrolled: 180 patients 
were randomly assigned to receive pembrolizumab 2 mg/
kg, 181 to receive pembrolizumab 10 mg/kg, and 179 
to receive chemotherapy. Progression-free survival was 
improved in patients assigned to pembrolizumab 2 mg/
kg (HR 0·57, 95% CI 0·45-0·73; P < 0·0001) and those 
assigned to pembrolizumab 10 mg/kg (0·50, 0·39-0·64; P 
< 0·0001) compared with those assigned to chemotherapy 
[120]. In the phase III clinical trial Keynote 006 trial was a 
Phase III clinical study in which 834 metastatic melanoma 
patients, were randomized 1:1:1 to receive Pembrolizumab 
10 mg/kg every 2 weeks up to 2 years, vs. 10 mg/kg every 
3 weeks up to 2 years, vs. ipilimumab 3 mg/kg every 3 
weeks for 4 cycles. Patients were enrolled regardless 
of BRAF status, and 2/3 of them were treatment naïve. 
Median PFS was superior in pembrolizumab groups (5.5 
months for pembrolizumab every 2 weeks, 4 months 
for pembrolizumab every 3 weeks and 2.8 months for 
ipilimumab, HR 0.58). Median OS was not reached in 
any of the treatment arms. One-year estimated OS rates 
were higher in the two pembrolizumab arms (74% for 
pembrolizumab every 2 weeks - HR = 0.63, 68% for 
pembrolizumab every 3 weeks - HR = 0.69, and 58.2% 
in ipilimumab group). At the pre-planned interim analysis 
the study was interrupted early for pembrolizumab 
superioriority in terms of Overal Survival, and cross-over 
was offered to patients on ipilimumab arm [13]. 
Several phase I studies evaluated activity of anti 
PD-L1 agents in melanoma cohorts. MPDL3280A, an 
IgG1engineered anti PD-L1 antibody reported a 39% 
ORR with a 43% 24-week progression free survival rate 
in 38 patients [15]. BMS-936559 a fully human IgG4 
anti PD-L1 antibody achieved a 17% ORR in 52 patients 
[16]. Preliminary data about MEDI4736, an enngenireed 
IgG1 kappa monoclonal antibody, suggest that patients 
with melanoma remained in the phase I study beyond 
12 week [17]. All these drugs showed modest toxicity 
profiles; attention is thus directed to their potential use 
in combinational regimens with other drugs commonly 
employed in melanoma treatment like BRAF and MEK 
inhibitors.
Combination of anti-CTLA-4 and anti-PD-1
The rationale to combine anti-PD-1 and anti-
CTLA-4 antibodies relays in their different mechanisms 
of action and their ability to modulate different phases of 
the interaction of tumor and immune system: anti-CTLA-4 
acts mainly in the priming phase while anti-PD-1 blocks 
the effector phase in local tumor tissue.
The combination of nivolumab and ipilimumab 
has shown significant activity and has been currently 
approved by FDA for the first line treatment in advanced 
BRAF negative melanoma. In phase III CheckMate 067 
trial, 945 previously untreated metastatic patients were 
randomized 1:1:1 to receive nivolumab monotherapy 
(dose 2 mg/kg every 14 days), nivolumab+ipilimumab 
combination (induction phase: nivolumab 1 mg/kg 
plus ipilimumab 3 mg/kg every 21 days for 4 cycles; 
mainainance phase: nivolumab 3 mg/kg every 14 days) 
or ipilimumab monotherapy (3 mg/kg every 21 days for 
4 cycles); the study was designed to compare ipilimumab 
with the combination arm or with nivolumab. Co-primary 
endpoints were PFS and OS. Ipilimumab resulted inferior 
to both, achieving a median PFS of 2.9 months vs. 11.5 
months (HR = 0.42; 99.5% CI, 0.31–0.57; P < 0.001) for 
nivolumab plus ipilimumab and 6.9 months (HR = 0.57; 
99.5% CI, 0.43-0.76; P < 0.001) for nivolumab. The 
objective response rates were 43.7% in the nivolumab arm, 
57.6% in the combination arm and 19% in the ipilimumab 
arm. The critical concern was toxicity: grade 3 or 4 AEs 
occurred in 55.0% in the nivolumab plus ipilimumab group 
vs. only 27.3% and 16.3% of patients in the ipilimumab 
group and in the nivolumab group, respectively. The 
most common AEs were diarrhea (8.3% vs. 4.5% vs. 
1.9%, respectively) and colitis (8.3% vs. 7.7% vs.0.6% 
respectively) [12]. 
In order to reduce the incidence of severe adverse 
events, another combination regimens have been 
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evaluated, with different drug dosage. In Keynote-029 
pembrolizumab 2 mg/kg every 21 days was combined in 
the first 4 cycles with ipilimumab at a reduced dose of 1 
mg/kg. Preliminary results showed high activity (PFS of 
70% at 6 months), similar to that observed with nivolumab 
1 mg/kg plus ipilimumab 3 mg/kg regimen, but with 25% 
immune-related grade 3-4 adverse events [14]. Other 
author evaluated this regimen in different treatment lines 
[121].
Immune checkpoint inhibitors sequences: anti-
CTLA-4 followed by anti-PD-1 and vice versa
Combined CTLA-4 and PD-1 inhibition is a valid 
therapeutic option for advanced melanoma. Phase 3 
trials showed the superiority of such approach when 
compared to single agent immune checkpoint inhibitors 
[18]. Nonetheless, the serious adverse event (AE) rate is 
a definite issue (55% CTCAE G3-G4 AEs in the phase 
III trial). Theoretically, an alternative choice might be the 
sequential, rather than concomitant, administration of anti-
CTLA-4 and anti-PD-1 monoclonal antibodies.
Anti-CTLA-4 agents can indeed upregulate 
PD-L1 expression, potentially enhancing the action 
of a subsequent PD1/PD-L1 inhibition in tumor 
microenvironment [19]. Nonetheless, patients with 
metastatic melanoma might need a rapid response, 
especially in presence of large tumor burden. In the 
adaptive immune response, CTLA-4 activation mediates 
an earlier phase than PD-1 one. In order to elicit an anti-
tumor response, ipilimumab needs to activate T cells, 
while anti-PD-1 antibodies can activate lymphocytes 
directly in tumor microenvironment. Such a biological 
aspect has a direct clinical implication, because in 
vivo ipilimumab activity is slower than nivolumab or 
pembrolizumab one. Therefore, the upfront administration 
of anti-PD1 antibodies could lead to rapid responses, and 
sequential ipilimumab could result in enhanced therapeutic 
activity. Such approach could avoid the serious toxicities 
related to combined immunotherapy as well.
Anti-PD1 followed by anti-CTLA4 
Different retrospective trial ivestigated the role of 
ipilimumab after treatment failure to anti-PD1 therapy 
[122]. Aya et al. reported a case series of 9 patients 
treated with ipilimumab after progression on anti-PD1 
antibodies. Two subjects (22%) had a partial response, 
while the remaining 78% (7 patients) experienced disease 
progression with a median a 3-month PFS and a 16-month 
OS. Serious AEs (≥ G3) were reported in five out of nine 
patients (55%) [20]. 
Another retrospective analysis was performed 
by Bowyer et al. on 40 melanoma patients treated with 
ipilimumab 3 mg/kg for 4 doses after progression to 
pembrolizumab or nivolumab. The objective response 
rate was 10%, but 35% of subjects experienced G3-G5 
immune-related AEs. Therefore, ipilimumab is able to 
induce responses in patients previously treated with single 
agent anti-PD1 treatment, but the safety of such approach 
could be a concern [21]. 
Anti-CTLA4 followed by anti-PD1
The reverse sequence, that is PD1 inhibition after 
progression on ipilimumab, was analyzed in retrospective 
studies.  Shreders et al. described a series of 116 
melanoma patients treated with pembrolizumab after anti-
CTLA4 failure. Subjects experiencing disease progression 
at least 90 days after ipilimumab start had higher objective 
response and clinical benefit rates (ORR and CBR, 
respectively) when compared with patients progressing in 
the first 3 months of treatment (ORR 49% vs 35%; CBR 
66% vs 46%). Moreover, outcomes with pembrolizumab 
were much better in subjects having a longer PFS (≥ 6 
months) than in rapid progressors. Indeed, ORR and CBR 
were 55% and 80%, respectively, in long-term ipilimumab 
responders, whereas these rates were much inferior (25% 
and 25%, respectively) in rapid progressors (PFS < 45 
days). [22] 
Anti-PD1 after progression on ipilimumab was 
investigated in uveal melanoma as well. In a case series 
involving 25 subjects treated with pembrolizumab 2 mg/
kg q21days, median PFS was 91 days and median OS 
was not reached after a median follow-up of 32 weeks. 
Serious (G3-G4) AEs were observed in 25% of patients 
(5/25) [23]. 
The only prospective trial studying immune 
checkpoint inhibitors sequences was published in 2016. 
Weber et al. conducted a randomised, open-label, phase 
2 study aimed at evaluating the sequencing treatments 
with ipilimumab and nivolumab. 140 patients were 
randomly assigned to induction with nivolumab 3 mg/kg 
every 14 days for 6 doses followed by a planned switch 
to intravenous ipilimumab 3 mg/kg every 21 days for 
4 doses, or the reverse sequence; after this first phase, 
both groups received intravenous nivolumab 3 mg/kg 
every 2 weeks until progression or unacceptable toxicity. 
During the whole study period, nivolumab followed by 
ipilimumab lead to a higher incidence of adverse events 
(63% G3-G4 AEs) than the reverse sequence (50% G3-G4 
AEs). Nevertheless, the former sequence was associated 
with a higher response rate than the latter (35% vs 10% at 
week 13; 41% vs 20% up to week 25) [24]. 
Both FDA and EMA approved ipilimumab, 
pembrolizumab and nivolumab as single agents, as well 
as ipilimumab and nivolumab in combination. Further 
prospective randomized studies are to be performed in order 
to evaluate the effectiveness and the safety of sequential 
anti-CTLA4 followed by anti-PD1 or vice versa. In fact, 
the optimal sequential approach remains an unmet clinical 
need, especially for patients unfit for the combination.
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Tissue biomarkers
In order to detect patients that benefit from immune 
checkpoint inhibitors, several trials investigated potential 
tissue and circulating biomarkers. PD-1 and PD-L1 
expression, tumour-infiltrating lymphocytes, the T-cell 
receptor repertoire, and mutational or neoantigen burden 
are the most studied biological tissue characteristics, but 
characterization of the tumor microenvironment immune 
state still needs to be improved. Further investigation into 
the relationships between all these aspects should be aimed 
at creating an optimized model for predicting response to 
anti-PD-1 or anti-PD-L1-based therapies.
PD-L1 expression on melanoma cells has been the 
first candidate as a biomarker for anti-PD-1 drugs, but 
in melanoma it has no established role: many studies 
evidenced a high proportion of objective response in 
patients that resulted PDL1 negative; also PFS and OS 
resulted improved irrespective of PDL1 expression. 
In Keynote -001 trial patients affected by metastatic 
melanoma with different grade of PD-L1 expression 
and treated with pembrolizumab showed a variable 
reduction in tumor dimention, with renge from 35% 
to 86%: even if it seems that lower PD-L1 expression 
correlate with lower response, the high rate of response 
doesn’t allow to prevent this group of patients from 
immunocheckpoints treatment. [123] The poor reliability 
of PD-L1 immunohistochemistry as a biomarker for anti-
PD-1 or anti-PD-L1 therapies is probably the result of 
multiple variables: PD-L1 expression is actually regulated 
by various mechanisms, including the MAPK and PI3K or 
Akt pathways, transcriptional factors HIF1, STAT3, and 
NFkB, and epigenetic factors [25]. It can be also expressed 
by immune cells in the tumor microenvironment. PD-L1 
expression can be transient, and intrapatient and even 
intratumour heterogeneity in PD-L1 tumor expression 
can exist [26] Eventually, different detecting antibodies, 
thresholds for positivity, and quantification techniques 
have been used, so data are hardly comparable among 
trials [27].
Several studies identify a role of tumor infiltrating 
lymphocite as a marker of activity of immunomodulating 
agent: its predictive role is discussed, because baseline 
CD8+ T-cell density overlapped between the patients with 
a response and those with disease progression. However, 
it is interesting to note that modification of infiltrating 
lymphocite density from margin to tumor improved 
in an higher percentage in responsive disease, both in 
ipilimumab [28] and in antiPD1 trial [29].
In a small study conducted on 23 patients treated 
with anti PD-1 pembrolizumab, next-generation 
sequencing was done on pretreatment melanoma tumors 
to capture all uniquely rearranged variable T-cell receptor 
β-chain regions. The study showed that the presence of 
a more clonal T-cell population correlates with benefit 
from anti-PD1 treatment more then heterogeneous T cell 
population. In fact, T-cell receptor β chain usage was more 
restricted in the responding patient group than in those 
with disease progression [28].
Schumaker et al classified all tumor types based 
on mutational load and postulated that tumor types 
with high mutational burdens are more responsive to 
immunotherapy strategies. Melanoma is located at the top 
of the classification: it has a high median mutational load, 
the greatest number of neoantigens, and it is responsive to 
checkpoint immunotherapies [30].
Multiple studies in different cancers corroborate the 
relationship between tumor load and immunosensibility. In 
melanoma, a study by Snyder and colleagues [31] showed 
a better clinical benefit from anti CTLA-4 therapies 
(ipilimumab or tremelimumab administered in 64 patients) 
in melanoma patients with a mutational load of more than 
100 non-synonymous somatic mutations based on tumor 
whole-exome sequencing. This mutational load cutoff 
was associated with longer overall survival compared 
with patients with a lower mutational load (p = 0.04 in 
the discovery set and p = 0.01 in the validation set by 
log rank test). Furthermore the study underlines the 
importance of neoepitopes: a neoepitope signature based 
on major histocompatibility complex (MHC) class I 
presentation was highly associated with clinical outcome 
with overlap in neoepitopes predicted to occur in many 
responding patients. It seems that the mutational load 
gives more immunosensibility in proportion of a higher 
probability to induce immunogenic neoepitope through 
passenger mutations. Also anti PD1/PDL1 drugs have 
been correlated with mutational load [32]. 65 patients 
with advanced melanoma were treated with nivolumab 
or pembrolizumab or atezolizumab and High mutational 
load, measured by hybrid capture-based next-generation 
sequencing, was associated with response to therapy 
and long median progression-free survival and overall 
survival.
Expression of immune-related genes can 
discriminate groups of melanoma responsive to 
immunotherapy. Studies of gene expression profiling 
showed that melanoma treated with immunocheckpoint 
inhibitors showed better treatment efficacy, if they 
expressed genes related to inflammatory response. In 
a retrospective analysis [33] of patients with advanced 
melanoma given ipilimumab in a phase 2 clinical trial 
(CA184004) the expression of 22 immune-related genes 
had at least a 2.5-times increase in responders. This gene 
profile included markers for cytotoxic T cells (eg, CD8A, 
granzyme B, perforin 1), Th1 cytokines or chemokines, 
MHC class II (HLA-DQA1), and other immune-related 
genes (eg, NKG7, IDO1). An interferon γ score was 
developed by Ribas and collegue [34]. These scores 
showed significant correlation with best overall response 
and progression-free survival to anti PD1. The gene score 
included those encoding interferon γ (IFNG), granzyme 
A and B (GZMA and GZMB), and perforin 1 (PFR1), 
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IDO1, LAG3, and other immune-related genes. In support 
of the importance of IFNy gene signature, Johnson and 
colleagues [35] showed that high MHC class II (HLA-
DR) expression was associated with improved clinical 
response, longer progression-free survival, and longer 
overall survival in patients with melanoma given anti-
PD-1 or anti-PD-L1 therapy.
Circulating biomarkers 
Blood-derived parameters have been correlated with 
survival of melanoma patients treated with antiCTLA4, 
including baseline absolute neutrophil count (ANC) or 
the neutrophil to lymphocyte ratio (NLR), known markers 
of systemic inflammation. The data from the Italian 
expanded access program with ipilimumab at 10 mg/kg 
demonstrated an increase in the number of circulating 
ICOS+T cells at week 7 in parallel to disease control and 
improved survival [36]. Increase of ANC observed 2 to 
8 weeks after initiation of Ipilimumab and expansion of 
activated T cells reflect change associated with positive 
outcome [37]. 
An increase in the eosinophil count > 100/
mm3 between the first and the second infusions and a 
lymphocyte count >1000/mm3 at the start of the second 
course were associated with an improved OS [38]. 
High NLR (neutrophil/lymphocyte) ratio, high ANC 
(> 2), before initiating ipilimumab treatment in patients 
with metastatic melanoma are independent prognostic 
indicators of poor survival [39].
Moreover, the derived NLR (dNLR), composed of 
white cell counts (WBC) and ANC, has been proposed as 
an alternative to NLR to detect a potential biomarker of 
response to ipilimumab. Prospectively collected data from 
720 advanced melanoma patients treated with ipilimumab 
3 mg/kg within Italian EAS were analyzed. Baseline 
ANC and derived neutophil to lymphocyte ratio (dNLR) 
were associated with outcome of ipilimumab melanoma 
patients. Patients with both ANC > 7500 and dNLR > 3 
had a significant increased risk of death and a progression 
Figure 1: Mechanisms of action of anti-CTLA4, anti-PD-1, and anti-PD-L1. Antigen Presenting Cells interact with Lymphocyte: 
the immunological synapses is composed by activation signals (exemplified in yellow) and inhibitory signals like CTLA4 (exemplified in 
red).CTLA4 is a target of AtiCTLA4 drugs. Activated Lymphocyte migrate to melanoma cells. The interaction between PDL1 (expressed 
by melanoma cells) and PD1 (expressed by Lymphocyte) causes Lymphocyte anergy. AntPD1 and ANtPDL1 drugs prevent this interaction.
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compared with patients with lower ANC and dNLR. The 
1 and 2 year survival rate were 2% and 0% respectively, 
for patients with ANC > 7500 and dNLR >3 and 43% and 
24%, respectively, for patients with both lower ANC and 
dNLR [40].
Since LDH levels and neurophil count were 
independent prognostic factors in melanoma, a study 
showed that ipilimumab may be the best treatment in 
patients with high neutrophil count and LDH, in particular 
when superior to 7.5 × 106/l and x 2 upper normal limit 
(UNL), respectively [41].
It was postulated also the evaluation of melanoma 
markers on circulating cells as Melan A, gp100, MAGE3, 
MIA (melanoma inhibitory antigen) prior to the treatment 
and within the therapy were compared to the data collected 
at baseline after the melanoma surgery. Lower levels were 
linked to longer survival time. A reduction by 30% at week 
6 to week 9 of ipilimumab administration was associated 
with response to therapy [42].
A significant decrease in myeloid-derived 
suppressor cells (MDSC) as immune-regulatory cells in 
concomitant with increase of fully activated type-1 CD4+/
CD8+ T cells and improved progression free survival was 
described (PFS) [43]. 
During ipilimumab treatment, MDSC frequencies 
did not change compared to baseline levels. MDSC 
frequencies in ipilumumab-treated patients were 
independently of baseline serum lactate dehydorgenase 
levels but tended to increase in patients with metastasis 
in skin or lymph nodes only (M1a). Clinical responder to 
ipilimumab therapy showed less of MDSC as compared 
to non-responders. These data suggest that the frequency 
of MDSC may be used as a predictive marker of response 
while low frequencies identify patients more likely 
benefitting from ipilimumab treatment. Briefly, during 
treatment with Ipilimumab, disease control and survival 
were significantly associated with decreasing levels of 
lactate dehydorgenase [44], C-reactive protein, FOXP3 
regulatory T cells (Tregs), lower pretreatment level of 
circulating MDSC increasing absolute lymphocyte count 
between baseline and end of treatment [45], increase of 
ANC and CD4+/ICOShigh T cells [46]. 
Studies to identify peripheral blood immune 
biomarkers during anti-PD1 treatment illustrated that PD-1/
PD L1 blockade increases effector T-cell proliferation 
(CD8+/HLA-DR+/Ki67+ T cells), production of interferon-
gamma (IFN-γ) and IL-18, but without significant correlation 
with clinical response in patients. A better clinical response to 
pembrolizumab was noticed in melanoma patients who had 
TCR oligoclonality and a higher number of baseline CD8+ 
T cells. Moreover, tumor mutational load could be potential 
predictive biomarker for PD-1/PD- L1 blockade therapy: it is 
demonstrated that tumors with high mutational load are likely 
more immunogenic, due to higher production of neoantigens 
and consequent stimulation of neoantigen-specific CD4+ and 
CD8+ T cells [47].
Recently, a framework is proposed for describing 
the different interactions between cancer and the immune 
system in individual cases, with the aim to focus biomarker 
research and to help guide treatment choice. The outcome 
of cancer-immune interactions is based on a number of 
largely unrelated parameters such as tumor “foreignness” 
and T cell–inhibitory mechanisms. Seven parameter 
classes may constitute a reasonable initial framework for 
building the so-named “Cancer immunogram”, including 
the evaluation of tumor mutation load, lymphocyte count, 
intratumoral T cells, PD-L1 expression on tumor, serum 
levels of c-reactive protein (CRP), LDH and IL-6. Thus, 
the information obtained from the combination of tumor 
genomics, immunohistochemistry, and standard assays 
on the peripheral blood compartment to visualize the 
state of cancer-immune interactions in individual patients 
could help clinicians to define treatment options in a more 
refined and personalized manner [48].
New combinations on the horizon
In order to improve the activity of immune-
checkpoints inhibitors, their combination with different 
agents seems a promising strategy. Agents with different 
mechanisms of action and different safety profiles 
may potentially have a therapeutic synergistic effect 
in several cancer types or even overcome mechanisms 
of resistance [85–86]. Several trials studied the 
combination of immunocheckpoints inhibitors and other 
systemic treatment, such as vaccines, epidrugs, targeted 
therapies, different immunotherapies, (see Figure 2) and 
chemotherapy.
Immune check points inhibitors and vaccines
The rationale of developing anticancer vaccines 
dates back to the 1950s, when the presence of cancer-
specific antigens potentially inducing an immune response 
was first observed [49]. Since then many clinical trials of 
therapeutic vaccination have focused on melanoma, but 
results have been disappointing: indeed, the MMAIT-
IV phase III study unexpectedly showed worse survival 
in the vaccine arm with respect to placebo [50], while 
other randomized trials have not showed any benefit for 
various immunologically effective vaccines [51], despite 
they were all immunologically effective, i.e. capable of 
inducing an antigen-specific T-cell response.
Overall, these data suggest that the antitumor 
immunity developed after anticancer vaccination with 
current techniques is largely ineffective and not sufficient 
to obtain a clinically meaningful benefit in the majority 
of patients. Immune checkpoint inhibitors counteract 
some physiologic mechanisms suppressing the immune 
response (among others CTLA-4, PD-1/PD-L1, LAG-
3) and therefore, could be employed to boost a highly 
specific, vaccine-induced anticancer response, potentially 
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increasing efficacy. This strategy is also supported by 
preclinical data demonstrating enhanced vaccination-
induced priming of T cells after CTLA-4 blockade 
[52]. The first large-scale clinical trial evaluating this 
strategy was the MDX010-20 study, which compared 
the combination of ipilimumab plus gp100 vaccine with 
ipilimumab alone or gp100 alone. Both ipilimumab arms 
resulted superior to gp100 alone, without any meaningful 
difference between them [53].
Another smaller, phase II study in adjuvant 
setting evaluated the combination of ipilimumab with a 
multipeptide vaccine (tyrosinase, gp100 and MART-1), in 
view of the multiplicity of antigens potentially expressed 
by melanoma. Anyway the vaccine failed to show any 
significant clinical activity, and immunological activity 
was also disappointing: only 25% of patients developed 
immune response against gp100 or MART-1, and none to 
tyrosinase [54].
An alternative approach focused on the 
immunosuppressive role of indoleamine 2,3-dioxygenase 
(IDO), identified as one of the mechanisms of resistance 
to ipilimumab. In an attempt to target the enzyme, a small 
phase I clinical trial employed a combination of a peptide 
vaccine from IDO and ipilimumab. An immune response 
to the vaccine was detected in 3/10 patients and 5/10 
obtained a stable disease at first evaluation, suggesting 
that efficacy might not be superior to ipilimumab alone. 
The authors also reported a death presumably related to 
treatment-induced colitis.
PD-1 blocking antibodies have also been evaluated 
in combination with vaccines. Preclinical evidence 
actually showed vaccine-dependent PD-L1 upregulation in 
the tumor microenvironment, thus supporting this strategy 
[55]. A first trial evaluated a combination of nivolumab 
and a multipeptide vaccines targeting gp100, MART-1 e 
NY-ESO-1 in 90 patients with pretreated melanoma, either 
ipilimumab-naïve or refractory. Overall response rate was 
25%, with no difference related to previous ipilimumab 
administration, and disease control rate was 46%. 
Responders had less CD8+ cells specific for NY-ESO-1 
and MART-1 in the peripheral blood at baseline, whose 
increase after vaccination was not statistically significant 
[56]. A second trial evaluated the same combination as 
adjuvant therapy after complete resection for stage IIIC or 
IV melanoma. After treatment, patients showed increased 
peripheral CD8+ T cells specific for the vaccination 
antigens, suggesting that the vaccine may be more 
immunologically active in the adjuvant setting. From the 
clinical standpoint, the relapse rate of 30% after a median 
follow-up of 32.1 months may be encouraging, but further 
studies are needed to discern the relative contribution of 
vaccine and nivolumab, if any, to this result [57]. 
In summary, the studies conducted so far have shown 
that adding a peptide vaccine to the currently available 
immunomodulating antibodies is generally safe, but does 
not result in increased clinical activity or efficacy. However, 
peptide-based vaccines may be suboptimal: some studies 
actually suggest that dendritic cell (DC) vaccines may 
be more effective both immunologically and clinically 
[58]. To be used as a vaccine, DCs are generally obtained 
ex vivo, loaded with desired tumor antigens by different 
techniques, and finally administered to the patient. Such 
products, as conventional vaccines, are remarkably safe 
and immunologically effective [59]. Anyway, despite 
long-lasting clinical responses and encouraging survival 
have been reported [60], a single, small randomized trial 
failed to demonstrate superiority of a dendritic cell vaccine 
over dacarbazine in metastatic melanoma [61]. The sole 
clinical trial evaluating a combination of a DC vaccine with 
ipilimumab in 39 pretreated advanced melanoma patients, 
however, showed promising results: 51% of the patients 
were progression-free at 6 months, with an objective response 
rate of 38%. Immune-related toxicity was not marginal, but 
manageable and reversible with steroid therapy [62]. These 
preliminary results suggest that the combinations of DC 
vaccines and immune checkpoint inhibitors deserve further 
evaluation in prospective clinical trials.
Immunocheck points inhibitors and epidrugs 
Epigenetic is the field of biology that studies all 
the heritable and potentially reversible changes in gene 
expression that occur without altering DNA sequence 
[63]. The three main epigenetic fields are the following: 
microRNA, DNA methylation, histone modifications. 
MicroRNAs (miRNAs) are small single-stranded 
RNA molecules; they usually are of 22 nucleotides in 
length. MiRnas regulate gene expression modulating the 
post-trascription process. [64] 
DNA methylation occurs in the so called “CpG 
islands” that are part of the promoter region of genes and 
that are compoused by CpG dinucleotides. Methylation is 
catalyzed by DNA methyltransferase (DNMT) enzymes. 
Methylation levels induce different accessibility to gene 
transcription.
Histones are the primary component of chromatin; 
their function is organization of DNA into nucleosomes. 
Accessibility of genes to transcription factors is regulated 
by post-translational covalent histone modifications 
[65] which include methylation, phosphorylation and 
acetylation (that is catalyzed by histone acetyltransferases 
and deacetylases - HDACs). This last field is the most 
exploited in melanoma.
All epigenetic changes induce also an 
immunomodulation of the interaction between tumor and 
immune system. An increasing number of data shows that 
epigenetic drugs have a role in facilitating immunological 
targeting of cancer cells by modulating different molecules 
and pathways that mediate the interaction between the 
immune system and cancer cells.
HDAC and DNMT inhibitors can have some 
immunomodulatory effect: for example, they can result in 
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altered antigen presentation of PD1 and MHC and elevated 
immunogenicity as evidenced by increased expression of 
CD25, CD40 or CD80 and other costimulatory molecules; 
they can alter the FoxP3 expression, the function of DC, 
increase the activity of CDb+ lymphosites and decrease the 
activity of CD4*lymphosites. Further, they can induce G1 
cell cycle arrest with an increase in cyclin D1 impaired cell 
proliferation groth reduction and induction of apoptosis.
Thus, epigenetic drugs seem an option to overcome 
some limitations of currently available immunotherapeutic 
regimens and a strong rationale exists to use them in 
combination. A second generation epigenetic drugs with 
improved efficacy and clinical tolerability are now being 
developed. Preclinical data support the feasibility and 
activity of the proposed strategy. In particular, systemic 
administration of 5-AZA-CdR proved effective in 
modifying the immune phenotype of human metastatic 
melanoma xenografts, by inducing or up-regulating 
cellular CTA expression and expression of HLA class I 
antigens and HLA A1 and A2 allospecificities [66]. These 
in vivo modifications were remarkably durable; NY-
ESO-1 expression and HLA class I antigen up-regulation 
were still detectable on melanoma xenografts 30 days after 
the end of 5-AZA-CdR administration. Emphasizing the 
notion that epigenetic modification of tumor cells strongly 
up-regulates their immunogenicity, injection of BALB/c 
mice with 5-AZA-CdR-treated human melanoma cells 
generated high-titer anti- NY-ESO-1 antibodies [66]
Combinations of immune-checkpoints inhibitors 
and targeted therapies
Pre-clinical studies showing that combination of 
BRAF and MEK inhibitors has immuno-modulatory 
properties and may enhance immune activation [67–71] 
led to the investigation in clinical trials of regimens 
including MAPK inhibitors targeted therapies and 
immune-checkpoint inhibitors (Table 1).
Early phase clinical trials combining ipilimumab 
and BRAF/MEK inhibitors revealed severe toxicities. 
The phase I trial of ipilimumab plus vemurafenib 
(NCT01400451) was terminated early due to 
hepatotoxicity [72] and the phase I trial of ipilimumab plus 
dabrafenib and trametinib was suspended after 2/7 patients 
enrolled developed colitis with colonic perforation [73]; in 
the same study, no dose-limiting toxicities were observed 
in the cohort treated with ipilimumab plus dabrafenib.
PD-1/PD-L1 checkpoint inhibitors are associated 
with less severe toxicities than anti-CTLA-4 [74] thus 
making them ideal candidates to explore combinations 
with BRAF/MEK targeted therapies. In a phase I 
study of the PD-L1 inhibitor MEDI4736 given in 
triple combination with dabrafenib and trametinib 
(NCT02027961), only 3/26 patients receiving such 
regimen discontinued study treatments due to an adverse 
event, with no toxicities leading to death; dose-limiting 
toxicities were observed in only one patients treated with 
dabrafenib+trametinib+MEDI4736 (reversible grade 
3 thrombocytopenia). Despite the limitation due to the 
small number of patients, such triple combination showed 
promising clinical activity, with 69% of patients achieving 
a response and 100% achieving disease control [75].
Similar results were obtained in a phase Ib dose-
escalation study of vemurafenib plus atezolizumab 
(NCT01656642). Notably, in such study, a lower 
proportion of patients treated with a 28-days run-in 
treatment with only vemurafenib followed by concurrent 
administration with atezolizumab had grade 3 toxicities 
Figure 2: New Agent for combinations with immunotherapy: meccanism of action. (1) BRAF end MEK inhibitors block 
MAPKinasi pathway (indicated with RAS, BRAF, MEK, ERK in the figure). (2) Epigenetic drugs modulates proteins expression trough 
an alteration in usual DNA-RNA-protein sequence, and causing immnostimulation (see text). (3) Antigen (exemplified with triangles) 
vaccination: Vaccination stimulate dendritic cells to activate immunoresponse against melanoma cell. (4) IDO inhibitors repress T cell 
suppression by blocking tryptophan conversion. T VEC therapy cause local immunoinfiltration by causing local G CSF production.
Oncotarget12461www.impactjournals.com/oncotarget
compared with patients who received a front-line 
concurrent vemurafenib+atezolizumab treatment [76]. 
An additional cohort with a 28-days run-in treatment with 
vemurafenib and cobimetinib followed by concurrent 
triple administration with atezolizumab led to the opening 
of a large phase 3 randomized, placebo-controlled study 
(NCT02908672) to assess the efficacy of the triple 
combination compared with vemurafenib and cobimetinib 
only.
Pembrolizumab plus dabrafenib and trametinib 
is another triple combination assessed as a tolerable 
treatment in a phase I, dose-identification study, despite 
a considerable rate of grade 3-4 adverse events (67%) 
and discontinuation due to toxicity (33%) [77]. With a 
promising clinical activity being observed in the phase 
I study, such regimen is currently under investigation in 
a randomized, placebo-controlled phase II clinical trial 
(NCT02130466).
Immune checkpoint inhibitors and BRAF/MEK 
targeted therapy combinations showed promising clinical 
activity in early phase clinical trials, but at an increased 
rate of severe toxicities; therefore, such treatments may 
not be the best approach or suitable to all patients, and 
efforts should be addressed to the identification of 
predictive factors selecting patients at increased risk of 
severe toxicities. 
As long as the combined treatment of 
immunocheckpoints inhibitors and targeted therapies 
will remain an experimental option, in clinical practice 
the controversy remains over which is the best first-line 
choice in the BRAF mutated metastatic patient between 
immunotherapy and target therapy. If historically targeted 
therapies offered rapid shrinkage without long-term 
survival, today with the combination of MEK and BRAF 
inhibitors, Overal Survival curves are observed with a 
large share of long survivors [113], and it is evident that 
patients who benefit best from this strategy are low-tumor 
burden and low basal LDH patients [112]. If initially 
antiCTLA4 provided long-lasting survival for a minority 
share of patients at the expense of rapid progression of 
many, to date with the anti-pd1 and the combination of 
antiCTLA4 and anti PD1, the proportion of long surviving 
patients has increased considerably as the rapidity of 
achieving the answer [12]. The discussion is open and 
clinical and translational research will be the key to such 
questions.
Combinations of immune-checkpoints inhibitors 
and other immunotherapies
The combination of ipilimumab and nivolumab 
achieved higher clinical activity at the cost of significant 
toxicities. In addition to studies with anti-PD-1 in 
combination with low dose ipilimumab, other combination 
regimens are currently under investigation to achieve 
better efficacy outcomes with a lower impact on toxicity.
The combination of pembrolizumab and 
epacadostat, an orally available inhibitor of indoleamine 
2,3-dioxygenase (IDO1), was well-tolerated and achieved 
impressive results in a phase I study. IDO1 is a tryptophan-
catabolizing enzyme that is overexpressed in many 
cancers and induces immune tolerance by suppressing 
T-cell responses; IDO1 inhibition exhibits antitumor 
activity through the reactivation of effector T cells and is 
Table 1: Selected melanoma clinical trials exploring the combinations of immune-checkpoint 
inhibitors with BRAF/MEK targeted therapy (see attatched file)
Study Phase Status Treatment Strategy
NCT01400451 I Terminated due to dose 
limiting toxicities
Ipilimumab
Vemurafenib
Anti-CTLA-4
+
BRAFi
NCT01767454 I Completed Ipilimumab
Dabrafenib +/- Trametinib
Anti-CTLA-4
+
BRAFi+MEKi
NCT02027961 I Active, not recruiting MEDI4736
Dabrafenib +/- Trametinib
Anti-PD-L1
+
BRAFi+MEKi
NCT01656642 Ib Recruiting Atezolizumab
Vemurafenib +/- Cobimetinib
Anti-PD-L1
+
BRAFi+MEKi
NCT02130466 II Recruiting Pembrolizumab 
Dabrafenib + Trametinib
Anti-PD-1
+
BRAFi+MEKi
NCT02908672 III Not yet recruiting Atezolizumab
Vemurafenib +/- Cobimetinib
Anti-PD-L1
+
BRAFi+MEKi
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synergistic with PD-1 blockade [78–83] Such combination 
is currently being investigated in a randomized, placebo-
controlled phase III clinical trial (NCT02752074) [78].
Talimogene laherparepvec (T-VEC), a herpes 
simplex virus type 1–derived oncolytic immunotherapy 
designed to selectively replicate within tumors and 
produce granulocyte macrophage colony-stimulating 
factor (GM-CSF) to enhance systemic antitumor 
immune responses, produced durable responses and 
a therapeutic benefit against melanoma in a phase III 
clinical trial [84], and was recently approved by the 
FDA for the treatment of melanoma lesions in the skin 
and lymph nodes. Despite a lower clinical activity and 
efficacy than anti-PD-1 drugs, T-VEC demonstrated to 
be a very tolerable treatment, with only 4% patients 
discontinuing therapy as a result of adverse events in 
the phase 3 trial; therefore, it may represent a valuable 
option for combination therapy. The safety and activity 
of the combination of pembrolizumab and T-VEC, 
which increases tumor-derived antigen expression 
and T cell infiltrate and may act in synergy with 
PD-1 blockade, was explored in a phase Ib study: the 
combination was well tolerated, with no DLTs being 
observed and no patients discontinuing treatment due 
to treatment-related adverse events, and active, with 
an overall response rate of 56% [85–86]. Such results 
supported the conduction of a randomized, placebo-
controlled phase III trial to assess the efficacy of the 
combination of pembrolizumab and T-VEC compared 
with pembrolizumab as single agent (NCT02263508).
Immunocheckpoints inhibitors and 
chemotherapies
The strategy of combining chemotherapy and 
immunotherapy is based on the notion that combination 
regimens may potentiate the immune system to more 
easily recognize neoantigens released upon cytotoxic 
chemotherapy-induced tumor cell death [87–88].
The combination of chemotherapy and cytokines 
immunotherapy was variously assessed in several 
melanoma clinical trials, but failed to provide improved 
survival, despite a higher rate of responses compared to 
chemotherapy alone [89]. 
In spite of the lack of evidence showing an 
improvement of survival in metastatic melanoma patients, 
dacarbazine has been the drug most frequently used and 
compared, both as single agent or combined with other 
therapies in randomized studies [90–91]. Recently, 
immune-checkpoint inhibitors have become widely 
available for the treatment of advanced melanoma and 
the combination of such drugs with chemotherapy have 
been investigated. First, the combination of ipilimumab 
with dacarbazine was evaluated in a phase II study of 
ipilimumab 3 mg/kg plus dacarbazine 250 mg/m2 versus 
ipilimumab alone (MDX010-08). It was observed that 
adding dacarbazine to ipilimumab did not suppress but 
instead enhanced the effect of ipilimumab [92].
Five-years follow up of the phase III trial CA184-
024, which compared ipilimumab at 10mg/kg plus 
dacarbazine 850 mg/m2 with placebo plus dacarbazine 
in treatment-naïve patients with advanced melanoma 
showed an improvement in median overall survival for the 
combination arm with 11.2 versus 9.1 months (hazard ratio 
[HR], 0.72; 95% CI, 0.59 to 0.87; P = 0.001) [93]. No new 
toxicities were reported; however, severe liver toxicity 
was observed in the combination arm, with high rates 
of G3-4 adverse events, probably due to the additional 
hepatotoxicity of dacarbazine [94–96]. The 5-year survival 
analysis confirmed that approximately 20% of treated 
patients achieve long-term survival, similarly to rates 
observed for ipilimumab as single agent.
The combination of ipilimumab and fotemustine 
was also evaluated. Fotemustine, a nitrosurea alkylating 
agent able to pass the blood-brain barrier, has shown 
activity in patients with brain metastasis. In a phase III 
trial, a trend in favor of fotemustine was observed in 
terms of overall survival and, notably, a better time to 
BM was evidenced compared to dacarbazine in patients 
with stage IV melanoma [97]. An Italian phase II, open 
label, single arm study (NIBIT-M1) aimed at assessing 
the efficacy and safety of the combination of ipilimumab 
10 mg/kg plus fotemustine 100 mg/m2 in patients with 
stage IV melanoma, including patients with asymptomatic 
brain metastasis. The combination of ipilimumab plus 
fotemustine had clinical activity in a subset of patients 
with or without brain metastasis, despite greater toxicities 
(more than 50% of treated patients experienced G3-4 drug 
related adverse events) [98]. Ipilimumab plus fotemustine 
showed a clinical benefit in patients with brain metastasis. 
The combination seemed also to prevent or postpone the 
appearance of brain metastases.
A three-year survival analysis showed similar 
outcomes in patients with or without brain metastases, 
further supporting that such a combination might be 
effective in patients with NCS involvement. Median OS 
was 12.9 months [95% confidence interval (CI), 7.1–
18.7 months] for the whole study population, and 12.7 
months (95% CI, 2.7–22.7 months) for patients with brain 
metastases, respectively. The three-year survival rates 
were 28.5% for the whole study population and 27.8% for 
patient with brain metastasis [99].
After the encouraging results obtained with the 
combination of ipilimumab plus fotemustine, in particular 
in patients with brain metastasis, a second randomized 
phase III study (NIBIT-M2) comparing fotemustine 100 
mg/m2 vs fotemustine 100 mg/m2 plus ipilimumab 10 mg/
kg or ipilimumab 3mg/kg plus nivolumab 1 mg/kg) was 
initiated in order to evaluate the safety and specifically OS 
in patients with brain metastasis.
So far the combination of immune-checkpoint 
inhibitors and chemotherapy has not yielded the expected 
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results. However, the strong rationale supporting this 
strategy and the partial successes in specific subgroups of 
patients encourages further investigation. 
Abscopal effect and immunosystem
The abscopal effect of radiation is a rare 
phenomenon that occurs when tumor regression is 
observed in non-irradiated tumor sites after a local 
application of radiotherapy [100–101]. Studies 
reported that radiation improves antitumor response 
to immunotherapy through several mechanisms: 
enhancement of the major histocompatibility complex 
class I, expression of calreticulin and factor for surface 
apoptosis signals; activation of dendritic cells; enhanced 
cross-presentation of tumor antigens; increased density of 
tumor-infiltrating lymphocytes; changes in expression of 
immune checkpoint molecules; and modulation of Treg 
cell populations (101). Radiotherapy-induced cell death is 
a potential source of tumor antigens, which may indeed 
be uptaken, processed, and presented by dendritic cells to 
CD8+ T lymphocytes. 
Another possible explanation of the synergy 
between radiotherapy and immunostimulatory mAbs 
is that radiotherapy seems to induce a more intense 
expression of CD137 and/or PD1 on tumor-infiltrating 
T lymphocytes; moreover, radiotherapy causes vascular 
inflammation and activation of antigen-presenting 
dendritic cells (DCs) [102].
Systemic, immune-mediated abscopal effects 
on tumor regression have been detected in preclinical 
and early clinical trials because of the intensifying 
T-cell effects of the combinatorial therapies [100]. The 
combination of irradiation with immunotherapy may 
increase the occurrence of abscopal effect, with rates of 
25%–52% with immune checkpoint inhibitors [101].
Abscopal effect and anti-CTLA-4
Anecdotal evidence suggested that in patients treated 
with anti CTLA-4 mAb (ipilimumab) and subsequent 
palliative radiotherapy objective responses were detected 
outside the irradiation field, concurrent with increases in 
the titer of antibodies against the shared tumor antigen 
NY-ESO1 [103].
It has been speculated that such an antigen-
presenting cell subset is the main mediator of productive 
tumor antigen presentation to CD8+ T cells and the IFNa/b 
levels are critically involved in the radiotherapy-induced 
abscopal effects [104]. Genomic DNA released by dying 
tumor cells is probably involved in eliciting IFNa/b 
via endoplasmic-reticulum-associated protein STING 
(stimulator of IFN genes) and, in turn, IFNa/b may act 
on both cross-priming DCs and CD8+ T cells to favor, 
as a necessary factor, the immune response by T cell 
line. Strategies aiming at local enhancement of IFNa/b 
could render radiotherapy-induced tumor cell death more 
immunogenic as recently shown for chemotherapy [104].
The first case reported of abscopal effect was 
a patient with metastatic melanoma who underwent 
maintenance with ipilimumab and concurrent palliative 
radiotherapy (28.5 Gy) at disease progression resulted 
in regression of non-irradiated metastases that showed 
benefits for at least 10 months [105].
Hiniker and colleagues discussed to combine 
ipilimumab and concurrent radiotherapy for a patient with 
asymptomatic melanoma [106]. That patient was given 
a higher radiation dose (54 Gy in three fractions) and 
showed a complete response in both the primary tumor 
and the metastatic lesions, which confirms the findings 
from pre-clinical studies indicating the importance of 
radiation dose [107].
Many other reports also observed benefit of 
radiotherapy combined to ipilimumab in metastatic 
melanoma or NSCLC, including patients with complete 
responses [102].
Of note, a series enrolling 21 patients with advanced 
melanoma who progressed after ipilimumab and then 
underwent radiotherapy for cranial or extracranial sites 
observed an abscopal response in 11 patients (52%), 
including those with partial responses and with stable 
disease. The median time from radiotherapy to an abscopal 
response was 1 month (range, 1-4), and median overall 
survival was superior in patients exhibiting the abscopal 
effect compared with nonresponders (22.4 vs 8.3 months, 
respectively) [101, 107].
Another series included 47 metastatic melanoma 
patients who underwent radiotherapy following 
ipilimumab. A reduction of lesions was observed in 7 
patients (11%) before radiation therapy compared with 16 
(25%) after radiation therapy; in 11 of the latter (69%), an 
increase of lesions had been observed before radiotherapy 
(P = 0.03). The radiation fraction size < = 3 Gy was 
associated with favorable lesion response (P = 0.014) 
[101–108].
Chandra and collegues demonstrated no association 
between abscopal responses and either timing of 
ipilimumab in relation to radiotherapy or duration from 
first dose of ipilimumab to initiation of radiotherapy 
[109]. A subset of patients may have more favorable out-
of-field responses following treatment with radiation. 
Interestingly, it has been described that multiple fraction 
radiation regimens were associated with a more favorable 
response [109]. 
Abscopal effect and anti-PD1
The PD-L1 is another putative regulator of immune 
responses to radiation therapy [100]. Despite preclinical 
studies on its role in extending PFS and amplifying the 
abscopal response of radiation treatment [100], clinical data 
regarding abscopal effects with anti-PD1 are weak [101].
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Although low doses of radiation increase T-cell 
infiltration, they also upregulate or increase PD-L1 
expression levels on tumor cells and might contribute 
to radioresistance in tumors. Ribeiro and colleagues 
demonstrated an estimated rate of abscopal effect of 25% 
(3/12 patients), evaluating only patients with metastatic 
melanoma that had disease progression on anti-PD1, 
with radiotherapy median total dose of 24 Gy (1-40 Gy), 
averagely given in 3 fractions (1-10 fractions) [101].
Results from retrospective analyses indicated that 
the modality of the radiation treatment is crucial for 
minimizing toxicity. On this regard, significant reductions 
in toxicity have indeed been achieved with the use of more 
sophisticated radiation planning and treatment modalities, 
such as protons [106]. Questions arise also about the 
optimal time to begin radiotherapy as well as the right 
sequencing scheme between immune-modulation and 
radiation therapy in order to obtain an abscopal response 
[101].
Finally, it is difficult to discriminate on how much 
of the tumor response is due to systemic therapy alone or 
to combination treatment [101].
Real life setting: special populations
In the real life setting, the clinicians have to treat 
different types of patients that are not widely represented 
in clinical trials, where the treated populations are selected 
on the basis of inclusion criteria: examples are patients 
with ECOG Performance Status higher than 2, elderly, 
patients with comorbidity, especially autoimmune disease, 
patients with uncontrolled brain metastases.
Due to immunosenescence, it is has been 
hypothesized that older adults may benefit less from 
immunotherapy [114–115]. There is limited information 
about the efficacy and toxicity of CPI in older adults, 
mostly derived from subgroup analysis of larger clinical 
trials, and no substantial differences in efficacy or safety 
were reported in elderly patients [116, 117]. Regarding 
Ipilimumab, no difference in median OS was found by 
Sileni et al. between patients aged ≥70 years (8.9 months 
(95% CI 7.2–10.6)) and < 70 years (7.0 months (95% CI 
6.1–7.9); P = 0.17 with similar rates of immune related 
adverse events (irAE) [118]. Regarding AntiPD1, In 
CheckMate 066, in adults aged 65–75 and in >75 years 
aged treatment with nivolumab was associated with a 
HR of 0.44 (0.24–0.81) and a HR of 0.25 (0.10–0.61) 
respectively [11]. In CheckMate 069 the objective 
response rate was 64% in patients younger than 65 years 
compared to 53% in those aged 65 and older [12]. 
Some queries were about treating with 
immunocheckpoints patients with autoimmune 
comorbidities, because of possible exacerbations of 
autoimmune disorders. Major data about this issue derive 
from a retrospective study that reviewed 119 patients 
with either preexisting autoimmune disease and/or a 
history of irAEs during prior treatment with ipilimumab 
treated with anti–PD-1 therapy for advanced melanoma 
(30% of patients had active symptoms and 38% were on 
immunosuppressive agents): 38% of patients experienced 
a flare of their autoimmune, most of wich were mild in 
intensity. Efficacy was similar to literature: the overall 
response rate was 33%. As expected, the response rate in 
patients on immunosuppressants at the time of enrollment 
was lower [119].
In most phase II clincal trial, patients with clinical 
active untreated brain metastasis were excluded, and 
only stable treated brain lesions were admitted. Some 
retrospective trials evaluated the efficacy of antiPD1 
in this particular population. In a recent ASCO annual 
meeting, data from a Phase I/II study underline the activity 
of antiPD1 also in this population. More data are needed 
to validate these aspect.
CONCLUSIONS
Immune checkpoint inhibitors improved survival 
of melanoma patients and several strategies have been 
developed towards the improvement of their efficacy and 
activity. If the combination of anti-PD-1 and anti CTLA-
4 is a new efficient immunotherapy regimen, promising 
results derive from the associations of immunocheckpoint 
inhibitors and the different systemic agents. To this extent, 
a larger number of treatment strategies will be soon 
available for melanoma patients.
Tissue and circulating predictive factors are largely 
awaited to help physician in their clinical practice; this 
need will be even more crucial in the very next future 
in order to tailor a personalized strategy in every single 
patient.
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